Furthermore, a recent study in a lung tumour-bearing mouse model has also shown that fusing a tumour antigen peptide to annexin A5 (AnxA5) significantly enhances its immunogenicity and anti-tumour efficacy when administered after chemotherapy. This evidence concerns the gene ANXA5 and neoplasm.